Vaxcyte, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
PCVX$67.53+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net Loss | $(766,628) | $(463,927) | $(402,266) |
| Other comprehensive loss: | |||
| Unrealized gains (losses) on investments | 9,463 | (4,398) | 538 |
| Foreign currency translation adjustments, net | (4,003) | 346 | 2 |
| Comprehensive Loss | $(761,168) | $(467,979) | $(401,726) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.